M
Maarten C.C.M. Hulshof
Researcher at University of Amsterdam
Publications - 254
Citations - 9079
Maarten C.C.M. Hulshof is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Cancer & Chemoradiotherapy. The author has an hindex of 38, co-authored 218 publications receiving 6848 citations. Previous affiliations of Maarten C.C.M. Hulshof include Netherlands Cancer Institute & Rafael Advanced Defense Systems.
Papers
More filters
Journal ArticleDOI
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
Joel Shapiro,J. Jan B. van Lanschot,Maarten C.C.M. Hulshof,Pieter van Hagen,Mark I. van Berge Henegouwen,Bas P. L. Wijnhoven,Hanneke W. M. van Laarhoven,Grard A. P. Nieuwenhuijzen,Geke A. P. Hospers,Johannes J. Bonenkamp,Miguel A. Cuesta,Reinoud J. B. Blaisse,Olivier R. Busch,Fiebo J. W. ten Kate,Geert-Jan Creemers,Cornelis J. A. Punt,John T. M. Plukker,Henk M.W. Verheul,Ernst Jan Spillenaar Bilgen,Herman van Dekken,Maurice J.C. van der Sangen,Tom Rozema,Katharina Biermann,Jannet C. Beukema,Anna H.M. Piet,Caroline M. van Rij,Janny G. Reinders,Hugo W. Tilanus,Ewout W. Steyerberg,Ate van der Gaast +29 more
TL;DR: Long-term follow-up confirms the overall survival benefits for neoadjuvant chemoradiotherapy in patients with clinically resectable, locally advanced cancer of the oesophagus or Oesophagogastric junction and shows a significant increase in 5-year overall survival.
Journal ArticleDOI
Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma
Jens Overgaard,D. González González,Maarten C.C.M. Hulshof,Giorgio Arcangeli,Olav Dahl,O. Mella,Søren M. Bentzen +6 more
TL;DR: Adjuvant hyperthermia significantly improved local tumour control when applied in association with radiation in treatment of malignant melanoma, and successful local treatment of patients with a single or a few metastatic malign melanoma lesions has significant curative potential.
Journal ArticleDOI
Patterns of Recurrence After Surgery Alone Versus Preoperative Chemoradiotherapy and Surgery in the CROSS Trials
Vera Oppedijk,Ate van der Gaast,J. Jan B. van Lanschot,Pieter van Hagen,Rob M. van Os,Caroline M. van Rij,Maurice J.C. van der Sangen,Jannet C. Beukema,H.J.T. Rutten,Patty H. Spruit,Janny G. Reinders,Dick J. Richel,Mark I. van Berge Henegouwen,Maarten C.C.M. Hulshof +13 more
TL;DR: Preoperative CRT in patients with esophageal cancer reduced locoregional recurrence and peritoneal carcinomatosis and there was a small but significant effect on hematogenous dissemination in favor of the CRT group.
Journal ArticleDOI
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
Annemieke Cats,Edwin P.M. Jansen,Nicole C.T. van Grieken,Karolina Sikorska,Pehr Lind,Marianne Nordsmark,Elma Meershoek-Klein Kranenbarg,Henk Boot,Anouk K. Trip,HA A. Maurits Swellengrebel,Hanneke W. M. van Laarhoven,Hein Putter,Johanna W. van Sandick,Mark I. van Berge Henegouwen,Henk H. Hartgrink,Harm van Tinteren,Cornelis J.H. van de Velde,Marcel Verheij,Frits van Coevorden,Steven Vanhoutvin,Maarten C.C.M. Hulshof,Olaf Jl Loosveld,A (Bert) Jan Ten Tije,Frans L. G. Erdkamp,Fabiënne A. R. M. Warmerdam,Donald L. van der Peet,Henk M.W. Verheul,Djamila Boerma,Maartje Los,Annerie Slot,Danny Houtsma,Johanna E.A. Portielje,Reinoud J. B. Blaisse,Ernst Jan Spillenaar Bilgen,Marco B Polée,Maud M. Geenen,Jeffrey P.B.M. Braak,Karen J. Neelis,Marije Slingerland,Rob L. H. Jansen,Jeroen Buijsen,Aart Beeker,Quirijn A. J. Eijsbouts,Johanna Mgh Van Riel,Tom Rozema,Dick Johan van Spronsen,Jetske M. Meerum Terwogt,Bea C Tanis,Adelheid Me Van der Torren-Conze,Richard Van Hilligersberg,Miriam Koopman,Marien O Den Boer,Geert-Jan Creemers,Maurice J.C. van der Sangen,Marjolein Em Rentinck,H Pieter van den Berg,Ge Jpm Jonkers,Diane Grootenboers,Annelie Je Vulink,Sjoerd Hovenga,Huub van der Mijle,Arnold Baars,A. Haringhuizen,Marije Ie Appels,Ron C Rietbroek,Ellen M Hendriksen,Marie-Cecile Jc Legdeur,Daan Ten Bokkel Huinink,O Aart Van Dobbenburgh,Jitty M Smit,Aart Van Bochove,Gerrit-Jan Veldhuis,Erik W Muller,Johannes J. Bonenkamp,Pètra M Braam,Jaap De Boer,Henk K Van Halteren,Fransje Aa Valster,Alex L. T. Imholz,Marjan A Van Dijk,Ate van der Gaast,J (Hans)-Martin Mb Otten,Heleen M. Ceha,Bengt Glimelius,Cecillia Lagerbäck,Mats Perman,Anders Johnsson,David Borg,Niels H Nielsen,Andrzej Piwowar,Mattias Elmlund,Helene Hörberg,Per Edlund,Bengt Johansson,Petra Flygare,Marie Louise Jespersen +95 more
TL;DR: This investigator-initiated, open-label, randomised phase 3 trial aimed to compare perioperative chemotherapy with preoperative chemotherapy and postoperative chemoradiotherapy in patients with resectable gastric adenocarcinoma.
Journal ArticleDOI
Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Liselotte M. S. Boevé,Maarten C.C.M. Hulshof,André N. Vis,Aeilko H. Zwinderman,Jos W. R. Twisk,Wim P.J. Witjes,Karl P.J. Delaere,R. Jeroen A. van Moorselaar,Paul C.M.S. Verhagen,George van Andel +9 more
TL;DR: The current RCT comparing ADT to ADT with EBRT to the prostate in patients with primary bone mPCa did not show a significant difference in overall survival, although the CI cannot exclude a substantial survival benefit.